ZyVersa Therapeutics Inc. (NASDAQ: ZVSA)
$4.45
-0.4500 ( -9.18% ) 107.2K
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Market Data
Open
$4.45
Previous close
$4.90
Volume
107.2K
Market cap
$3.68M
Day range
$4.33 - $5.44
52 week range
$3.41 - $90.65
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k/a | Quarterly Reports | 16 | May 15, 2024 |
10-q | Quarterly Reports | 55 | May 15, 2024 |
8-k | 8K-related | 14 | Apr 25, 2024 |
8-k | 8K-related | 13 | Apr 17, 2024 |
10-k | Annual reports | 94 | Mar 25, 2024 |
def | Proxies and info statements | 4 | Mar 19, 2024 |
8-k | 8K-related | 14 | Mar 08, 2024 |
pre | Proxies and info statements | 1 | Mar 08, 2024 |
8-k | 8K-related | 14 | Mar 01, 2024 |
8-k | 8K-related | 13 | Dec 22, 2023 |